Search

Your search keyword '"Sung, Sue Hee"' showing total 296 results
Start Over Author "Sung, Sue Hee"
296 results on '"Sung, Sue Hee"'

51. THE USE OF NATURAL LANGUAGE PROCESSING-BASED ALGORITHMS AND OUTPATIENT CLINICAL ENCOUNTERS FOR WORSENING HEART FAILURE: INSIGHTS FROM THE UTILIZE-WHF STUDY

Author

Ambrosy, Andrew P., primary, Parikh, Rishi, additional, Sung, Sue Hee, additional, Narayanan, Anand, additional, Masson, Rajeev, additional, Lam, Phuong-Quang, additional, Kheder, Kevin, additional, Iwahashi, Alan, additional, Hardwick, Alexander, additional, Fitzpatrick, Jesse, additional, Avula, Harshith, additional, Shen, Xian, additional, Sanghera, Navneet, additional, Cristino, Joaquim, additional, and Go, Alan, additional

Published
2021
Full Text
View/download PDF

52. GLOBAL CARDIOVASCULAR RISK ASSESSMENT IMPROVES RISK STRATIFICATION FOR MAJOR ADVERSE CARDIAC EVENTS ACROSS A WIDE RANGE OF TRIGLYCERIDE LEVELS IN STATIN-TREATED INDIVIDUALS: INSIGHTS FROM THE KP REACH STUDY

Author

Ambrosy, Andrew P., primary, Yang, Jingrong, additional, Fitzpatrick, Jesse, additional, Wagner, Jeffrey, additional, Kong, Jeremy, additional, Sung, Sue Hee, additional, Allen, Amanda, additional, Philips, Sephy, additional, Granowitz, Craig, additional, Abrahamson, David, additional, and Go, Alan, additional

Published
2021
Full Text
View/download PDF

55. Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVID‐19 pandemic.

Author

Ambrosy, Andrew P., Malik, Umar I., Leong, Thomas K., Allen, Amanda R., Sung, Sue Hee, and Go, Alan S.

Subjects
COVID-19 pandemic, VEGETARIANS, FOOD security, HEART failure, COVID-19, ADULTS, CARDIAC research
Abstract

Background: The impact of the novel coronavirus disease 2019 (COVID‐19) pandemic on diet and nutrition among older adults with chronic medical conditions have not been well‐described. Methods: We conducted a survey addressing (1) food access, (2) diet quality and composition, (3) nutritional understanding, and (4) attitudes towards research among adults with heart failure (HF) within an integrated health system. Adults (≥18 years) with diagnosed HF and at least one prior hospitalization for HF within the last 12 months were approached to complete the survey electronically or by mail. Outcomes included all‐cause and HF‐specific hospitalizations and all‐cause death was ascertained via the electronic health record. Results: Among 1212 survey respondents (32.5% of eligible patients) between May 18, 2020 and September 30, 2020, mean ± SD age was 77.9 ± 11.4 years, 50.1% were women, and median (25th–75th) left ventricular ejection fraction was 55% (40%–60%). Overall, 15.1% of respondents were food insecure, and only 65% of participants answered correctly more than half of the items assessing nutritional knowledge. Although most respondents were willing to participate in future research, that number largely declined for studies requiring blood draws (32.2%), study medication (14.4%), and/or behavior change (27.1%). Food security, diet quality, and nutritional knowledge were not independently associated with outcomes at 90 or 180 days. Conclusion: In a cohort of older adults with HF and multiple comorbidities, a significant proportion reported issues with food access, diet quality, and nutritional knowledge during the COVID‐19 pandemic. Future research should evaluate interventions targeting these domains in at‐risk individuals. Key points: Upwards of 15% of respondents screened positive for food insecurity, and only approximately 65% of respondents answered more than half of the items correctly on a questionnaire assessing nutritional understanding.Although the majority of respondents indicated that would be willing to consider participating in future research, that proportion declined markedly for studies requiring blood draws, study drugs, and/or behavior change.None of the functional domains assessed by this survey were independently associated with clinical outcomes in our cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

57. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia

Author

Ambrosy, Andrew P., primary, Fitzpatrick, Jesse K., additional, Tabada, Grace H., additional, Gurwitz, Jerry H., additional, Artz, Andrew, additional, Schrier, Stanley L., additional, Rao, Sunil V., additional, Reynolds, Kristi, additional, Smith, David H., additional, Peterson, Pamela N., additional, Fortmann, Stephen P., additional, Sung, Sue Hee, additional, Cohen, Harvey Jay, additional, and Go, Alan S., additional

Published
2020
Full Text
View/download PDF

64. Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) Study

Author

Fang, Margaret C, Fan, Dongjie, Sung, Sue Hee, Witt, Daniel M, Schmelzer, John R, Williams, Marc S, Yale, Steven H, Baumgartner, Christine, and Go, Alan S

Subjects
610 Medicine & health
Abstract

BACKGROUND Few studies describe both inpatient and outpatient treatment and outcomes of patients with acute venous thromboembolism in the US. METHODS A multi-institutional cohort of patients diagnosed with confirmed pulmonary embolism and/or deep venous thrombosis during years 2004 through 2010 was established from four large, US-based integrated healthcare delivery systems. Computerized databases were accessed and medical records reviewed to collect information on patient demographics, clinical risk factors, initial antithrombotic treatment, and vital status. Multivariable Cox regression models were used to estimate the risk of death at 90days. RESULTS The cohort comprised 5497 adults with acute venous thromboembolism. Pulmonary embolism was predominantly managed in the hospital setting (95.0%) while 54.5% of patients with lower extremity thrombosis were treated as outpatients. Anticoagulant treatment differed according to thromboembolism type: 2715 (93.7%) of patients with pulmonary embolism and 1634 (87.4%) of patients with lower extremity thrombosis were discharged on anticoagulants, compared to 288 (80.7%) patients with upper extremity thrombosis and 70 (55.6%) patients with other thrombosis. While 4.5% of patients died during the index episode, 15.4% died within 90days. Pulmonary embolism was associated with a higher 90-day death risk than lower extremity thrombosis (adjusted hazard ratio [aHR] 1.23 [1.04-1.47]) as was not being discharged on anticoagulants (aHR 5.56 [4.76-6.67]). CONCLUSIONS In this multicenter, community-based study of patients with acute venous thromboembolism, anticoagulant treatment and outcomes varied by thromboembolism type. Although case-fatality during the acute episode was relatively low, 15.4% of people with thromboembolism died within 90days of the index diagnosis.

Published
2019
Full Text
View/download PDF

67. Noncardiac-Related Morbidity, Mobility Limitation, and Outcomes in Older Adults With Heart Failure.

Author

Tisminetzky, Mayra, Gurwitz, Jerry H, Fan, Dongjie, Reynolds, Kristi, Smith, David H, Fouayzi, Hassan, Sung, Sue Hee, Goldberg, Robert, and Go, Alan S

Subjects
OLDER people, DISEASES, COMORBIDITY, HEART failure, COHORT analysis, RESEARCH, RESEARCH methodology, RETROSPECTIVE studies, EVALUATION research, MEDICAL cooperation, COMPARATIVE studies, SYMPTOMS, RESEARCH funding
Abstract

Background: To examine the individual and combined associations of noncardiac-related conditions and mobility limitation with morbidity and mortality in adults with heart failure (HF).Methods: We conducted a retrospective cohort study in a large, diverse group of adults with HF from five U.S. integrated healthcare delivery systems. We characterized patients with respect to the presence of noncardiac conditions (<3 vs ≥3) and/or mobility impairment (defined by the use/nonuse of a wheelchair, cane, or walker), categorizing them into four subgroups. Outcomes included all-cause death and hospitalizations for HF or any cause.Results: Among 114,553 adults diagnosed with HF (mean age: 73 years old, 46% women), compared with <3 noncardiac conditions/no mobility limitation, adjusted hazard ratios (HR) for all-cause death among those with <3 noncardiac conditions/mobility limitation, ≥3 noncardiac conditions/no mobility limitation, ≥3 noncardiac conditions/mobility limitation (vs) were 1.40 (95% CI, 1.31-1.51), 1.72 (95% CI, 1.69-1.75), and 1.93 (95% CI, 1.85-2.01), respectively. We did not observe an increased risk of any-cause or HF-related hospitalization related to the presence of mobility limitation among those with a greater burden of noncardiac multimorbidity. Consistent findings regarding mortality were observed within groups defined according to age, gender, and HF type (preserved, reduced, mid-range ejection fraction), with the most prominent impact of mobility limitation in those <65 years of age.Conclusions: There is an additive association of mobility limitation, beyond the burden of noncardiac multimorbidity, on mortality for patients with HF, and especially prominent in younger patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

71. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network

Author

Greenlee, Robert T., primary, Go, Alan S., additional, Peterson, Pamela N., additional, Cassidy‐Bushrow, Andrea E., additional, Gaber, Charles, additional, Garcia‐Montilla, Romel, additional, Glenn, Karen A., additional, Gupta, Nigel, additional, Gurwitz, Jerry H., additional, Hammill, Stephen C., additional, Hayes, John J., additional, Kadish, Alan, additional, Magid, David J., additional, McManus, David D., additional, Multerer, Deborah, additional, Powers, J. David, additional, Reifler, Liza M., additional, Reynolds, Kristi, additional, Schuger, Claudio, additional, Sharma, Param P., additional, Smith, David H., additional, Suits, Mary, additional, Sung, Sue Hee, additional, Varosy, Paul D., additional, Vidaillet, Humberto J., additional, and Masoudi, Frederick A., additional

Published
2018
Full Text
View/download PDF

73. Initial Management and Outcomes after Superficial Thrombophlebitis: The CVRN VTE Study

Author

Samuelson, Bethany, Go, Alan S., Sung, Sue Hee, Fan, Dongjie, and Fang, Margaret C.

Subjects
Male, Anticoagulants, Disease Management, Humans, Female, Venous Thromboembolism, Middle Aged, Thrombophlebitis, Pulmonary Embolism, Article, California, Platelet Aggregation Inhibitors, Retrospective Studies
Abstract

Although superficial thrombophlebitis (SVTE) is generally considered a benign, self-limited disease, accumulating evidence suggests that it often leads to more serious forms of venous thromboembolism. We reviewed the medical charts of 329 subjects with SVTE from the Cardiovascular Research Network Venous Thromboembolism cohort study to collect information on the acute treatment of SVTE and subsequent diagnosis of deep venous thrombosis within 1 year. All participants received care within Kaiser Permanente Northern California, a large, integrated healthcare delivery system. Fourteen (4.3%) subjects with SVTE received anticoagulants, 148 (45.0%) were recommended antiplatelet agents or nonsteroidal anti-inflammatory drugs, and in 167 (50.8%) there was no documented antithrombotic therapy. In the year after SVTE diagnosis, 19 (5.8%) patients had a subsequent diagnosis of a deep venous thrombosis or pulmonary embolism. In conclusion, clinically significant venous thrombosis within a year after SVTE was uncommon in our study despite infrequent use of antithrombotic therapy. Journal of Hospital Medicine 2016;11:432-434. © 2016 Society of Hospital Medicine.

Published
2016

77. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators

Author

Bansal, Nisha, primary, Szpiro, Adam, additional, Masoudi, Frederick, additional, Greenlee, Robert T, additional, Smith, David H, additional, Magid, David J, additional, Gurwitz, Jerry H, additional, Reynolds, Kristi, additional, Tabada, Grace H, additional, Sung, Sue Hee, additional, Dighe, Ashveena, additional, Cassidy-Bushrow, Andrea, additional, Garcia-Montilla, Romel, additional, Hammill, Stephen, additional, Hayes, John, additional, Kadish, Alan, additional, Sharma, Param, additional, Varosy, Paul, additional, Vidaillet, Humberto, additional, and Go, Alan S, additional

Published
2016
Full Text
View/download PDF

79. Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes.

Author

Ambrosy, Andrew P, Gurwitz, Jerry H, Tabada, Grace H, Artz, Andrew, Schrier, Stanley, Rao, Sunil V, Barnhart, Huiman X, Reynolds, Kristi, Smith, David H, Peterson, Pamela N, Sung, Sue Hee, Cohen, Harvey Jay, and Go, Alan S

Abstract

Limited data exist on the epidemiology, evaluation, and prognosis of otherwise unexplained anaemia of the elderly in heart failure (HF). Thus, we aimed to determine the incidence of anaemia, to characterize diagnostic testing patterns for potentially reversible causes of anaemia, and to evaluate the independent association between incident anaemia and long-term morbidity and mortality.

Published
2019
Full Text
View/download PDF

80. Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter‐Defibrillator Therapies.

Author

Hajduk, Alexandra M., Gurwitz, Jerry H., Tabada, Grace, Masoudi, Frederick A., Magid, David J., Greenlee, Robert T., Sung, Sue Hee, Cassidy‐Bushrow, Andrea E., Liu, Taylor I., Reynolds, Kristi, Smith, David H., Fiocchi, Frances, Goldberg, Robert, Gill, Thomas M., Gupta, Nigel, Peterson, Pamela N., Schuger, Claudio, Vidaillet, Humberto, Hammill, Stephen C., and Allore, Heather

Subjects
IMPLANTABLE cardioverter-defibrillators, COMORBIDITY, DISEASE risk factors, CHRONIC disease treatment, TREATMENT effectiveness, CARDIAC arrest prevention, CARDIAC pacing, CHRONIC diseases, LEFT heart ventricle, RISK assessment, SHOCK (Pathology), VENTRICULAR tachycardia, RELATIVE medical risk, DISEASE complications
Abstract

OBJECTIVE: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN: Retrospective cohort study. SETTING: Seven US healthcare delivery systems. PARTICIPANTS: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter‐defibrillator (ICD) for primary prevention. MEASUREMENTS: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0‐3, 4‐5, 6‐7 and 8‐16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4‐8), with 98% having at least two comorbidities. During a mean 2.2 years of follow‐up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14‐3.31] for 4‐5 comorbidities; HR = 2.25 [95% CI = 1.25‐4.05] for 6‐7 comorbidities; and HR = 2.91 [95% CI = 1.54‐5.50] for 8‐16 comorbidities). Participants with 8‐16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43‐3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67‐6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07‐2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

84. Abstract 16941: Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter Defibrillators (ICDs): Insights From the Cardiovascular Research Network Longitudinal Study of ICDs

Author

Greenlee, Robert T, primary, Go, Alan S, additional, Magid, David J, additional, Peterson, Pamela N, additional, Cassidy-Bushrow, Andrea E, additional, Gaber, Charles, additional, Garcia-Montilla, Romel, additional, Glenn, Karen A, additional, Gupta, Nigel, additional, Gurwitz, Jerry H, additional, Hammill, Stephen C, additional, Hayes, John J, additional, Kadish, Alan, additional, McManus, David D, additional, Multerer, Deborah, additional, Powers, J. David, additional, Reifler, Liza M, additional, Reynolds, Kristi, additional, Schuger, Claudio, additional, Sharma, Param P, additional, Smith, David H, additional, Suits, Mary, additional, Sung, Sue Hee, additional, Varosy, Paul D, additional, Vidaillet, Humberto J, additional, and Masoudi, Frederick A, additional

Published
2015
Full Text
View/download PDF

86. Patterns of Complex Comorbidity in Older Patients with Heart Failure

Author

Saczynski, Jane S., Gurwitz, Jerry H., Padmanabhan, Sandhyasree, Goldberg, Robert J., Magid, David J., Smith, David H., Sung, Sue Hee, and Go, Alan S.

Abstract

Background Heart failure (HF) carries a high burden of comorbidity with approximately one half of patients with HF having at least one additional comorbid condition present. Rates of comorbidity in patients with HF have steadily increased over the past 2 decades. Objective To examine patterns of comorbidity among older patients with HF in the Cardiovascular Research Network PRESERVE cohort. Methods PRESERVE Cohort Data are from the CVRN PRESERVE cohort which is a multicenter cohort of 37,054 patients [mean age = 74 years (SD = 12.4 yrs); 46% female] with HF diagnosed between 2005 and 2008 currently being conducted at 4 CVRN sites: KPNC, KPCO, KPNW, and FCHP. The primary data source for the PRESERVE cohort was the HMO Research Network Virtual Data Warehouse. Identification of Coexisting Diseases Coexisiting illnesses at the time of HF diagnosis were based on diagnoses and procedures mapped to relevant International Classification of Diseases, Ninth Edition (ICD-9) codes. For the purposes of characterizing clusters of comorbidities, we focused on coexisting conditions with a prevalence rate of ≥3%. Statistical Analysis We used the Agglomerative Clustering technique to characterize patterns of comorbidity. Over multiple iterations, each condition is clustered with the condition with which it has the highest squared correlation. This process is repeated to determine whether assigning a condition to a different cluster increases the amount of explained variance [ranging from 1.0 (all variance explained) to 0.0 (no variance explained)]. The conditions in each cluster are as correlated as possible among themselves and as uncorrelated as possible with conditions in other clusters. Results Burden of Comorbidity There was a high degree of comorbidity and multi-morbidity among patients with HF. (Table 1) Hypertension and arrhythmias were the comorbidities of HF that occurred most often in the absence of other chronic conditions (4.8% and 4.7%, respectively). The average number of comorbid conditions varied from 3.5 to 5.2. Patients with HF and unstable angina or other thromboembolic disorders had the highest multi-morbidity (mean = 5.2 conditions), whereas those with HF and hypertension had the lowest (mean = 3.5). Clustering of Comorbiditites A five-cluster structure was derived. Cluster 1: Dyslipidemia, Hypertension, Diabetes Mellitus, Visual Impairment Cluster 2: Acute Myocardial Infarction, Unstable Angina, Thromboembolic Disorder, Dementia Cluster 3: Aortic Valvular Disease, Cancer, Hearing Impairment, Arrthythmia Cluster 4: Peripheral Arterial Disease, Stroke Cluster 5: Lung Disease, Liver Disease, Depression Discussion and Conclusions Cluster analysis is an innovative approach to examining the co-occurrence of diseases and allows for identification of broad patterns of multi-morbidity beyond the pairings of diseases or disease counts. Patients with HF have a high rate of multi-morbidity, with an average of 4 co-occurring conditions. Intuitive and unintuitive patterns of clustering were identified. Randomized clinical trials in HF will need to include more diverse patient populations in order to adapt to the increasingly complex patient population. A cluster analysis approach to characterizing patterns of comorbidity may help indentify important patient subgroups.

Published
2011
Full Text
View/download PDF

95. Longitudinal Study of Implantable Cardioverter-Defibrillators

Author

Masoudi, Frederick A., primary, Go, Alan S., additional, Magid, David J., additional, Cassidy-Bushrow, Andrea E., additional, Doris, Jonathan M., additional, Fiocchi, Frances, additional, Garcia-Montilla, Romel, additional, Glenn, Karen A., additional, Goldberg, Robert J., additional, Gupta, Nigel, additional, Gurwitz, Jerry H., additional, Hammill, Stephen C., additional, Hayes, John J., additional, Jackson, Nathaniel, additional, Kadish, Alan, additional, Lauer, Michael, additional, Miller, Aaron W., additional, Multerer, Deborah, additional, Peterson, Pamela N., additional, Reifler, Liza M., additional, Reynolds, Kristi, additional, Saczynski, Jane S., additional, Schuger, Claudio, additional, Sharma, Param P., additional, Smith, David H., additional, Suits, Mary, additional, Sung, Sue Hee, additional, Varosy, Paul D., additional, Vidaillet, Humberto J., additional, and Greenlee, Robert T., additional

Published
2012
Full Text
View/download PDF

97. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators

Author

Bansal, Nisha, Szpiro, Adam, Masoudi, Frederick, Greenlee, Robert T, Smith, David H, Magid, David J, Gurwitz, Jerry H, Reynolds, Kristi, Tabada, Grace H, Sung, Sue Hee, Dighe, Ashveena, Cassidy-Bushrow, Andrea, Garcia-Montilla, Romel, Hammill, Stephen, Hayes, John, Kadish, Alan, Sharma, Param, Varosy, Paul, Vidaillet, Humberto, and Go, Alan S

Abstract

ObjectivePatients with chronic kidney disease (CKD) have higher risk of sudden cardiac death; however, they may not receive implantable cardioverter defibrillators (ICDs), in part due to higher risk of complications. We evaluated whether CKD is associated with greater risk of device-delivered shocks/antitachycardia pacing (ATP) therapies among patients receiving a primary prevention ICD.MethodsWe studied participants in the observational Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter Defibrillators. CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes included all delivered shocks/ATPs therapies and type of shock/ATP therapies (inappropriate or appropriate, determined by physician adjudication) within the 3 years. We evaluated the associations between CKD and time to first device therapy, burden of device therapy, and inappropriate versus appropriate device therapy, adjusting for demographics, comorbidity, laboratory values and medication use.ResultsAmong 2161 participants, 1066 (49.3%) had CKD (eGFR 44±11 mL/min/1.73 m2) at ICD implantation. During mean of 2.26±0.89 years, 9.8% and 18.5% of participants had at least one inappropriate and appropriate shock/ATP therapies, respectively. CKD was not associated with time to first shock/ATP therapies (adjusted HR 0.87, 95% CI 0.73 to 1.05), overall burden of shock/ATP therapies (adjusted relative rate 0.93, 95% CI 0.74 to 1.17) or inappropriate versus appropriate shock/ATP therapies (adjusted relative risk 0.88, 95% CI 0.68 to 1.14) compared with not having CKD.ConclusionsIn adults receiving a primary prevention ICD, mild-to-moderate CKD was not associated with the timing, burden or appropriateness of subsequent device therapy. Potential concern for inappropriate ICD-delivered therapies should not preclude ICDs among eligible patients with CKD.

Published
2017
Full Text
View/download PDF

98. Eligibility and Potential Benefit of Transcatheter Edge-to-Edge Repair in a Contemporary Cohort with Heart Failure: Evidence from a Large Integrated Health Care Delivery System

Author

Ambrosy, Andrew P., Yang, Jingrong, Tai, Andrew S., Dimbil, Sadia J., Garcia, Elisha A., Sung, Sue Hee, Bhatt, Ankeet S., Solomon, Matthew D., Ku, Ivy A., Mishell, Jacob M., McNulty, Edward J., Zaroff, Jonathan G., Rassi, Andrew N., Kong, Jeremy, and Go, Alan S.

Abstract

The eligibility and potential benefit of transcatheter edge-to-edge repair (TEER) in addition to guideline-directed medical therapy to treat moderate-severe or severe secondary mitral regurgitation (MR) has not been reported in a contemporary heart failure (HF) population. In this study 50,841 adults with HF identified between 2013-2018 were screened for TEER eligibility based on the Food and Drug Administration (FDA) labeling. After applying the FDA eligibility criteria, 2,461 of these patients (4.8%) qualified for TEER (FDA+). These patients had higher natriuretic peptide levels and were more likely to have had a prior 1-year HF hospitalization. The estimated number needed to treat to prevent or postpone all-cause hospitalization was 4.4, 8.8 for HF hospitalization, and 5.3 for all-cause death at 24 months. The low prevalence of FDA eligibility for TEER treatment was primarily due to absence of moderate-severe or severe MR. Additional research is necessary to validate the scope of eligibility and comparative effectiveness of TEER.

Published
2023
Full Text
View/download PDF

99. The Cardiovascular Research Network

Author

Go, Alan S., primary, Magid, David J., additional, Wells, Barbara, additional, Sung, Sue Hee, additional, Cassidy-Bushrow, Andrea E., additional, Greenlee, Robert T., additional, Langer, Robert D., additional, Lieu, Tracy A., additional, Margolis, Karen L., additional, Masoudi, Frederick A., additional, McNeal, Catherine J., additional, Murata, Glen H., additional, Newton, Katherine M., additional, Novotny, Rachel, additional, Reynolds, Kristi, additional, Roblin, Douglas W., additional, Smith, David H., additional, Vupputuri, Suma, additional, White, Robert E., additional, Olson, Jean, additional, Rumsfeld, John S., additional, and Gurwitz, Jerry H., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results